10 Things Worth Pay...
Health Care: Drugs
CytRx Corporation (CYTR: NASDAQ)
$3.58 -0.30 | -7.73%
06/04/12 - 04:00 PM ET
Company Balance Sheet
| Dec 2011 | Dec 2010 | Dec 2009 | Dec 2008 | |
| Assets | ||||
|---|---|---|---|---|
| Cash and Equivalents | 17.99M | 6.32M | 9.89M | 25.04M |
| Receivables | 216.98K | 895.79K | 789.62K | 342.90K |
| Inventories | 0.00 | 0.00 | 0.00 | 0.00 |
| Other Current Assets | 0.00 | 6.94M | 73.63K | 0.00 |
| Total Current Assets | 37.28M | 35.97M | 34.59M | 25.87M |
| Property, Plant & Equipment, Gross | 430.34K | 398.19K | 333.96K | 3.05M |
| Accumulated Depreciation & Depletion | 164.00K | 79.00K | 159.00K | 1.11M |
| Property, Plant & Equipment, Net | 266.34K | 319.19K | 174.96K | 1.94M |
| Intangibles | 0.00 | 0.00 | 0.00 | 0.00 |
| Other Non-Current Assets | 123.27K | 220.29K | 323.24K | 330.03K |
| Total Non-Current Assets | 573.38K | 723.26K | 681.97K | 2.45M |
| Liabilities & Shareholder Equity | ||||
| Total Assets | 37.85M | 36.70M | 35.28M | 28.32M |
| Accounts Payable | 6.63M | 1.03M | 1.07M | 668.42K |
| Short Term Debt | 0.00 | 0.00 | 0.00 | 0.00 |
| Other Current Liabilities | 0.00 | 2.44M | 3.37M | 0.00 |
| Total Current Liabilities | 13.60M | 6.13M | 6.93M | 5.04M |
| Long Term Debt | 0.00 | 0.00 | 0.00 | 0.00 |
| Deferred Income Taxes | 0.00 | 0.00 | 0.00 | 0.00 |
| Other Non-Current Liabilities | 0.00 | 0.00 | 0.00 | 7.58M |
| Minority Interest | 0.00 | 0.00 | 0.00 | 0.00 |
| Total Non-Current Liabilities | 0.00 | 0.00 | 0.00 | 7.58M |
| Total Liabilities | 13.60M | 6.13M | 6.93M | 12.63M |
| Preferred Stock Equity | 0.00 | 0.00 | 0.00 | 0.00 |
| Common Stock Equity | 24.25M | 30.57M | 28.35M | 15.70M |
| Common Par | 149.06K | 109.84K | 109.54K | 93.98K |
| Additional Paid In Capital | 237.32M | 229.25M | 227.44M | 210.01M |
| Cumulative Translation Adjustment | 0.00 | 0.00 | 0.00 | 0.00 |
| Retained Earnings | -210.94M | -196.52M | -196.92M | -192.12M |
| Treasury Stock | -2.28M | -2.28M | -2.28M | -2.28M |
| Other Equity Adjustments | 0.00 | 0.00 | 0.00 | 0.00 |
| Total Capitalization | 24.25M | 30.57M | 28.35M | 15.70M |
| Total Equity | 24.25M | 30.57M | 28.35M | 15.70M |
| Total Liabilities & Stock Equity | 37.85M | 36.70M | 35.28M | 28.32M |
| Total Common Shares Outstanding | 21.29M | 15.69M | 15.65M | 13.34M |
| Preferred Shares | 0.00 | 0.00 | 0.00 | 0.00 |
| Treasury Shares | 90.54K | 90.54K | 90.54K | 90.54K |
| Basic Weighted Shares Outstanding | 17.94M | 15.64M | 14.28M | 13.05M |
| Diluted Weighted Shares Outstanding | 17.94M | 15.92M | 14.28M | 13.05M |
| Number of Employees | 15 | 15 | 15 | 31 |
| Number of Part-Time Employees | 0 | 0 | 0 | 4 |
Portfolios with CYTR
- Portfolio NameUser Type
- Uservlady 1
- Contributor5 Stocks Under-$10 Setting ...
- UserHope For The Best
- Userrick epple
- ContributorBarron's Research Reports 1...
- UserNat's
- UserHi Potential
- Usernewintrade Portfolio 1
- Usersteveandvickie Portfolio 1
- Useractive-jrd
Latest CYTR Headlines from TheStreet
- 5 Stocks Under $10 With Big Upside Potential 11.18.11 | 06:11 am
- SeaChange, Tenet: Early Volume Plays 12.03.09 | 08:12 am
- CytRx: FDA Lifts 2-year Hold On Arimoclomol Tests 12.02.09 | 09:12 am
- Correction: CytRx FDA Letter 09.09.09 | 04:09 pm
- CytRx Expects To File FDA Response In 4Q 09.08.09 | 10:09 am
- CytRx Rises On Preclinical Data For Stroke Drug 08.24.09 | 01:08 pm
- Movers Roundup: Massey Energy, MannKind 06.08.09 | 02:06 pm
- CytRx Rises On Analyst's 'Outperform' Rating 06.08.09 | 01:06 pm
- Biotech Notebook: Nastech, Amgen, PDL BioPharma 11.15.07 | 04:11 pm
- Wednesday's Health Winners & Losers 11.14.07 | 03:11 pm
Press Releases for CYTR
- CytRx To Hold Conference Call Today At 10:00 A.m. Eastern Time To Discuss Favorable Results From INNO-206 Clinical Trial In Soft Tissue Sarcoma - Business Wire 06.04.12 | 08:06 am
- CytRx Announces Favorable Results From Phase 1b/2 Clinical Trial With INNO-206 - Business Wire 06.03.12 | 09:06 am
- CytRx Regains NASDAQ Compliance - Business Wire 06.01.12 | 08:06 am
- CytRx Announces The Publication Of INNO-206 Findings In Multiple Myeloma In Clinical Cancer Research - Business Wire 05.29.12 | 08:05 am
- CytRx Initiates Phase 2 Clinical Trial With INNO-206 In Pancreatic Cancer - Business Wire 04.26.12 | 08:04 am
- CytRx Receives NASDAQ Extension - Business Wire 04.23.12 | 08:04 am
- CytRx Announces Issuance Of Key U.S. Patent Covering INNO-206 Linker Technology - Business Wire 04.12.12 | 08:04 am
- CytRx’s INNO-206 To Be Featured In Two Presentations At The American Association For Cancer Research (AACR) 2012 Annual Meeting - Business Wire 03.27.12 | 08:03 am
- CytRx Reports 2011 Financial Results - Business Wire 03.13.12 | 08:03 am
- CytRx To Present At The Roth Capital Partners Annual OC Growth Stock Conference - Business Wire 03.05.12 | 08:03 am
Partner Headlines for CYTR
- Biotechs to Watch at the 2012 San Francisco Healthcare Confrences - Analyst Blog - Zacks 01.09.12 | 07:01 am
- Why CytRx Corporation Is Still A Big Biotech 'If' Play - Seeking Alpha 12.14.11 | 09:12 am
- CytRx Is Poised For Growth - Analyst Blog - Zacks 08.13.11 | 12:08 am
- CytRx Reports 2Q 2011 Results - Analyst Blog - Zacks 08.12.11 | 06:08 pm
- As the Market Dips, It's Time to Look for Biotech Sector Deals - Seeking Alpha 06.12.11 | 09:06 am
- CytRx Completes Sale of Molecular Chaperone Assets - Analyst Blog - Zacks 05.17.11 | 09:05 am
- Company News for April 29, 2011 - Corporate Summary - Zacks 04.29.11 | 10:04 am
- Stocks Mixed at Session's Half on Slowing Q1 Economy; Crude Futures Advance - NASDAQ 04.28.11 | 04:04 pm
- Mid-Day Update: Stocks Mixed as GDP Data Weighs; Jobless Claims Rise - NASDAQ 04.28.11 | 04:04 pm
- China Analyst: 10 Pharma Stocks With Highest Growth Potential - Seeking Alpha 10.08.10 | 06:10 am
